Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23314912 | 0.85 | TAS1R3 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2730606 | 0.82 | USP2 (0.35) | — | |
| SCHEMBL20711929 | 0.81 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL410168 | 0.81 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22808748 | 0.79 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21482325 | 0.79 | CA1 (0.44) | — | |
| SCHEMBL10578119 | 0.79 | PPARA (0.31) | — | |
| SCHEMBL10578124 | 0.79 | PPARA (0.31) | — | |
| SCHEMBL21913977 | 0.78 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25811458 | 0.77 | USP2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-21 | — | — | US | disclosed |
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | CHRNB2 4884/4885CHRNB4 4883/4885CHRNA3 4536/4885 |
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | CHRNB2 4884/4885CHRNB4 4883/4885CHRNA3 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.